---
document_datetime: 2025-11-23 08:05:44
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/rebetol.html
document_name: rebetol.html
version: success
processing_time: 0.1209585
conversion_datetime: 2025-12-26 10:40:38.737809
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Rebetol

[RSS](/en/individual-human-medicine.xml/66497)

##### Withdrawn

This medicine's authorisation has been withdrawn

ribavirin

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Rebetol](#news-on)
- [More information on Rebetol](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 18 October 2023, the European Commission withdrew the marketing authorisation for Rebetol (ribavirin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Merck Sharp &amp; Dohme B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Rebetol was granted marketing authorisation in the EU on 7 May 1999 for the treatment of hepatitis C. The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2004. It was then granted unlimited validity in 2009.

The European Public Assessment Report (EPAR) for Rebetol is updated to indicate that the marketing authorisation is no longer valid.

Rebetol : EPAR - Summary for the public

English (EN) (193.98 KB - PDF)

**First published:** 22/10/2009

**Last updated:** 07/11/2023

[View](/en/documents/overview/rebetol-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-245)

български (BG) (267.2 KB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/bg/documents/overview/rebetol-epar-summary-public_bg.pdf)

español (ES) (194.58 KB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/es/documents/overview/rebetol-epar-summary-public_es.pdf)

čeština (CS) (241.62 KB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/cs/documents/overview/rebetol-epar-summary-public_cs.pdf)

dansk (DA) (193.39 KB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/da/documents/overview/rebetol-epar-summary-public_da.pdf)

Deutsch (DE) (203.24 KB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/de/documents/overview/rebetol-epar-summary-public_de.pdf)

eesti keel (ET) (188.11 KB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/et/documents/overview/rebetol-epar-summary-public_et.pdf)

ελληνικά (EL) (287.48 KB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/el/documents/overview/rebetol-epar-summary-public_el.pdf)

français (FR) (197.41 KB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/fr/documents/overview/rebetol-epar-summary-public_fr.pdf)

hrvatski (HR) (230.58 KB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/hr/documents/overview/rebetol-epar-summary-public_hr.pdf)

italiano (IT) (196.03 KB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/it/documents/overview/rebetol-epar-summary-public_it.pdf)

latviešu valoda (LV) (245.9 KB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/lv/documents/overview/rebetol-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (237.77 KB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/lt/documents/overview/rebetol-epar-summary-public_lt.pdf)

magyar (HU) (230.14 KB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/hu/documents/overview/rebetol-epar-summary-public_hu.pdf)

Malti (MT) (245.17 KB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/mt/documents/overview/rebetol-epar-summary-public_mt.pdf)

Nederlands (NL) (199.38 KB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/nl/documents/overview/rebetol-epar-summary-public_nl.pdf)

polski (PL) (246.5 KB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/pl/documents/overview/rebetol-epar-summary-public_pl.pdf)

português (PT) (195.53 KB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/pt/documents/overview/rebetol-epar-summary-public_pt.pdf)

română (RO) (246.75 KB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/ro/documents/overview/rebetol-epar-summary-public_ro.pdf)

slovenčina (SK) (238.23 KB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/sk/documents/overview/rebetol-epar-summary-public_sk.pdf)

slovenščina (SL) (234.18 KB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/sl/documents/overview/rebetol-epar-summary-public_sl.pdf)

Suomi (FI) (187.35 KB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/fi/documents/overview/rebetol-epar-summary-public_fi.pdf)

svenska (SV) (191.87 KB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/sv/documents/overview/rebetol-epar-summary-public_sv.pdf)

Rebetol : EPAR - Risk-management-plan summary

English (EN) (1.86 MB - PDF)

**First published:** 14/10/2019

**Last updated:** 07/11/2023

[View](/en/documents/rmp-summary/rebetol-epar-risk-management-plan-summary_en.pdf)

## Product information

Rebetol : EPAR - Product Information

English (EN) (4.78 MB - PDF)

**First published:** 22/10/2009

**Last updated:** 07/11/2023

[View](/en/documents/product-information/rebetol-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-915)

български (BG) (6.25 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/bg/documents/product-information/rebetol-epar-product-information_bg.pdf)

español (ES) (4.7 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/es/documents/product-information/rebetol-epar-product-information_es.pdf)

čeština (CS) (5.65 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/cs/documents/product-information/rebetol-epar-product-information_cs.pdf)

dansk (DA) (4.75 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/da/documents/product-information/rebetol-epar-product-information_da.pdf)

Deutsch (DE) (6.29 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/de/documents/product-information/rebetol-epar-product-information_de.pdf)

eesti keel (ET) (4.38 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/et/documents/product-information/rebetol-epar-product-information_et.pdf)

ελληνικά (EL) (6.47 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/el/documents/product-information/rebetol-epar-product-information_el.pdf)

français (FR) (5.51 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/fr/documents/product-information/rebetol-epar-product-information_fr.pdf)

hrvatski (HR) (5.21 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/hr/documents/product-information/rebetol-epar-product-information_hr.pdf)

íslenska (IS) (4.62 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/is/documents/product-information/rebetol-epar-product-information_is.pdf)

italiano (IT) (5.19 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/it/documents/product-information/rebetol-epar-product-information_it.pdf)

latviešu valoda (LV) (5.78 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/lv/documents/product-information/rebetol-epar-product-information_lv.pdf)

lietuvių kalba (LT) (5.62 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/lt/documents/product-information/rebetol-epar-product-information_lt.pdf)

magyar (HU) (5.33 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/hu/documents/product-information/rebetol-epar-product-information_hu.pdf)

Malti (MT) (7 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/mt/documents/product-information/rebetol-epar-product-information_mt.pdf)

Nederlands (NL) (4.76 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/nl/documents/product-information/rebetol-epar-product-information_nl.pdf)

norsk (NO) (4.55 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/no/documents/product-information/rebetol-epar-product-information_no.pdf)

polski (PL) (6.55 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/pl/documents/product-information/rebetol-epar-product-information_pl.pdf)

português (PT) (4.78 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/pt/documents/product-information/rebetol-epar-product-information_pt.pdf)

română (RO) (6.09 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/ro/documents/product-information/rebetol-epar-product-information_ro.pdf)

slovenčina (SK) (5.66 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/sk/documents/product-information/rebetol-epar-product-information_sk.pdf)

slovenščina (SL) (5.46 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/sl/documents/product-information/rebetol-epar-product-information_sl.pdf)

Suomi (FI) (5.5 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/fi/documents/product-information/rebetol-epar-product-information_fi.pdf)

svenska (SV) (4.42 MB - PDF)

**First published:**

22/10/2009

**Last updated:**

07/11/2023

[View](/sv/documents/product-information/rebetol-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0093/G 24/11/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Rebetol : EPAR - All Authorised presentations

English (EN) (37.03 KB - PDF)

**First published:** 26/01/2007

**Last updated:** 07/11/2023

[View](/en/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-281)

български (BG) (129.37 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/bg/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_bg.pdf)

español (ES) (39.26 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/es/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_es.pdf)

čeština (CS) (126.16 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/cs/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (39.69 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/da/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (40.61 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/de/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (40.3 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/et/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (128.61 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/el/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_el.pdf)

français (FR) (39.17 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/fr/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (316.27 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/hr/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (129.49 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/is/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_is.pdf)

italiano (IT) (39.44 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/it/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (126.46 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/lv/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (126.57 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/lt/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (129.81 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/hu/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (172 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/mt/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (38.92 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/nl/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (131.73 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/no/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_no.pdf)

polski (PL) (131.54 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/pl/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_pl.pdf)

português (PT) (39.71 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/pt/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_pt.pdf)

română (RO) (119.76 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/ro/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (126.46 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/sk/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (124.32 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/sl/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (40.24 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/fi/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (39.8 KB - PDF)

**First published:**

26/01/2007

**Last updated:**

07/11/2023

[View](/sv/documents/all-authorised-presentations/rebetol-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Rebetol Active substance ribavirin International non-proprietary name (INN) or common name ribavirin Therapeutic area (MeSH) Hepatitis C, Chronic Anatomical therapeutic chemical (ATC) code J05AP01

### Pharmacotherapeutic group

- Antivirals for systemic use
- Antivirals for treatment of HCV infections

### Therapeutic indication

Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.

Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) not previously treated and without liver decompensation.

## Authorisation details

EMA product number EMEA/H/C/000246 Marketing authorisation holder

Merck Sharp and Dohme B.V

Waarderweg 39

Opinion adopted 20/09/2018 Marketing authorisation issued 06/05/1999 Withdrawal of marketing authorisation 18/10/2023 Revision 39

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Rebetol : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (1.29 MB - PDF)

**First published:** 22/10/2009

**Last updated:** 07/11/2023

[View](/en/documents/procedural-steps-after/rebetol-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Rebetol-H-C-PSUSA-00010007-202007 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/155557/2021

English (EN) (168.49 KB - PDF)

**First published:** 30/06/2021

**Last updated:** 07/11/2023

[View](/en/documents/scientific-conclusion/rebetol-h-c-psusa-00010007-202007-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Rebetol-H-C-246-II-0074: EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/174072/2015

English (EN) (1.86 MB - PDF)

**First published:** 09/12/2015

**Last updated:** 07/11/2023

[View](/en/documents/variation-report/rebetol-h-c-246-ii-0074-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Rebetol

Adopted

Reference Number: EMA/CHMP/408137/2015

English (EN) (125.43 KB - PDF)

**First published:** 25/09/2015

**Last updated:** 07/11/2023

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rebetol_en.pdf-1)

Rebetol-H-C-PSUSA-10007-201307 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/317751/2014

English (EN) (114.24 KB - PDF)

**First published:** 10/06/2014

**Last updated:** 07/11/2023

[View](/en/documents/scientific-conclusion/rebetol-h-c-psusa-10007-201307-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Rebetol-H-C-246-WS-0216 : EPAR - Assessment Report - Variation

Adopted

English (EN) (2.3 MB - PDF)

**First published:** 30/05/2012

**Last updated:** 07/11/2023

[View](/en/documents/variation-report/rebetol-h-c-246-ws-0216-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Rebetol

Adopted

Reference Number: EMA/CHMP/114050/2012

English (EN) (177.69 KB - PDF)

**First published:** 17/02/2012

**Last updated:** 07/11/2023

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rebetol_en.pdf-0)

Rebetol-H-C-246-II-0048 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/26308/2010

English (EN) (441.73 KB - PDF)

**First published:** 22/01/2010

**Last updated:** 07/11/2023

[View](/en/documents/variation-report/rebetol-h-c-246-ii-0048-epar-assessment-report-variation_en.pdf)

Rebetol-H-C-246-II-0049 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/6094/2010

English (EN) (417.7 KB - PDF)

**First published:** 22/01/2010

**Last updated:** 07/11/2023

[View](/en/documents/variation-report/rebetol-h-c-246-ii-0049-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Rebetol

Adopted

Reference Number: EMEA/CHMP/609356/2009

English (EN) (63.8 KB - PDF)

**First published:** 24/09/2009

**Last updated:** 07/11/2023

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rebetol_en.pdf)

Rebetol-H-C-246-II-0035 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (525.99 KB - PDF)

**First published:** 03/12/2007

**Last updated:** 07/11/2023

[View](/en/documents/scientific-discussion-variation/rebetol-h-c-246-ii-0035-epar-scientific-discussion-variation_en.pdf)

Rebetol-H-C-246-X-0016 : EPAR - Scientific Discussion - Extension

Adopted

English (EN) (811.38 KB - PDF)

**First published:** 11/08/2006

**Last updated:** 07/11/2023

[View](/en/documents/scientific-discussion-variation/rebetol-h-c-246-x-0016-epar-scientific-discussion-extension_en.pdf)

Rebetol : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (164.46 KB - PDF)

**First published:** 11/08/2006

**Last updated:** 07/11/2023

[View](/en/documents/steps-after-cutoff/rebetol-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Rebetol : EPAR - Procedural steps taken before authorisation

English (EN) (140.51 KB - PDF)

**First published:** 11/08/2006

**Last updated:** 07/11/2023

[View](/en/documents/procedural-steps/rebetol-epar-procedural-steps-taken-authorisation_en.pdf)

Rebetol : EPAR - Scientific Discussion

English (EN) (1.07 MB - PDF)

**First published:** 11/08/2006

**Last updated:** 07/11/2023

[View](/en/documents/scientific-discussion/rebetol-epar-scientific-discussion_en.pdf)

#### News on Rebetol

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 September 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-september-2015) 25/09/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 February 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-february-2012) 17/02/2012

#### More information on Rebetol

- [Ribavirin - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/ribavirin)

**This page was last updated on** 07/11/2023

## Share this page

[Back to top](#main-content)